Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OUCRU’s Director, Professor Guy Thwaites, has recently contributed to an analysis of antibacterial agents in preclinical and clinical development by the World Health Organisation (WHO), as part of the WHO advisory group on research and development of antibacterial treatments.

Various coloured pills

The advisory group met virtually on 29 and 30 November 2021 to discuss and evaluate pipelines of antibacterial candidates in different stages of development around the globe. The resulting report – titled “2021 Antibacterial agents in clinical development and preclinical: an overview and analysis” – covers 77 antibacterial agents in clinical development, 45 of which are traditional (direct-acting small molecules) agents and 32 are non-traditional agents.

The report shows that the development of new antibacterial treatments is insufficient to tackle the increasing threat of antibiotic resistance. The number of new antibiotics in the preclinical stage has remained relatively constant over the last 3 years. However, in the clinical stage, there were only 27 new products against priority pathogens in 2021, compared to 31 products in 2017. Amongst those, only 6 fulfill at least one of WHO’s criteria for innovation. This is due to barriers such as the lengthy approval pathway, high cost, low success rates, and impact of the COVID-19 pandemic.

The 2021 analysis suggests that the issue demands urgent and concerted efforts from both governments and the private sector. They need to work together to accelerate the innovation of antibiotics, especially those that can make an impact in low-resource settings where antimicrobial resistance is most visible. There should also be collaboration across countries to create sustainable solutions, enhance research and development, as well as establish a viable ecosystem for antibiotics.

Visit Professor Guy Thwaites research profile

The full story is available on the OUCRU website

Similar stories

Letter from the hills: The invisible burden of leprosy in Sumba

OUCRU Indonesia launches a new exhibition by photographer Yoppy Pieter based in Jakarta, Indonesia. This exhibition documents, through a series of intimate and beautiful images, the invisible burden of leprosy and other skin diseases in Sumba, an island in Nusa Tenggara Timor province, Indonesia.

Combating Antimicrobial Resistance

November 18 – 24 is World Antimicrobial Awareness Week. Antimicrobial resistance has been a key focus in OUCRU’s research for many years. Our objective is to understand and improve antimicrobial use and antimicrobial resistance in agriculture, the community, and hospitals. Our approach is interdisciplinary – led by a number of OUCRU’s research groups and public engagement teams.

OUCRU Engagement around mental health

OUCRU’s Public and Community Engagement team develops training and resources on the topic of stress management and communication skills. Run by the Public and Community Engagement team, the Youth Ambassadors programme also links young people to medical research that impacts their lives and connects researchers to the health issues that young people care about.

Abhilasha Karkey, new OUCRU Nepal Director

OUCRU Nepal is pleased to announce that as of 01 October 2022, Dr Abhilasha Karkey will assume the role of Director.

OUCRU presents a new virtual exhibition: Digital Diaries, Voices from the Pandemic, COVID-19 experiences in Asia

This online exhibition showcases short films and photographs created by health-care workers and community members and documents the socio-cultural impact of the COVID-19 pandemic in Indonesia, Nepal and Vietnam.

World Hepatitis Day: OUCRU research seeks to lower cost of treatment and improve access to care for patients with hepatitis C

Today is World Hepatitis Day. OUCRU and hospitals in Ho Chi Minh City and Hanoi have been collaborating on hepatitis C clinical trials since 2018. Our research is centred around predictive factors for selecting persons who could be successfully treated with shorter durations of antiviral therapy. OUCRU’s social science and public engagement teams are currently working with underrepresented groups to create community-led strategies to link care and treatment for populations at risk for viral hepatitis. Our aim is to have a more significant impact on the treatment strategy and access to care for patients with hepatitis C in Vietnam and worldwide in the future.